• Manuel A Baños-González, Antonio González-Hermosillo, Milton E Guevara-Valdivia, Jorge A Vázquez-Acosta, Manuel O de Los Ríos-Ibarra, Julio A Aguilar-Linares, Carlos Cantú-Brito, José L Leiva-Pons, Gerardo Pozas-Garza, Eddie A Favela-Pérez, Luis Molina, Reynaldo Magaña-Magaña, Rocío Camacho-Casillas, Eduardo Chuquiure-Valenzuela, Janneth Manzano-Cabada, and Manlio F Márquez-Murillo.
• Center of Research and Post-degree, Health Sciences Academic Division, Universidad Juárez Autónoma de Tabasco, Tabasco.
• Gac Med Mex. 2023 Jan 1; 159 (1): 243124-31.

IntroductionHeart failure in patients with non-valvular atrial fibrillation (NVAF) is two to three times more common than in individuals without NVAF.ObjectiveTo identify cardiometabolic risk factors (CMRF) and antithrombotic treatment in patients with NVAF and heart failure with reduced ejection fraction (HFrEF), and to determine if there were differences according to gender.MethodsCMRF, pro-thrombotic risk, bleeding risk, and antithrombotic therapy were globally analyzed and according to gender.ResultsOut of 1,423 patients with NVAF, 336 had HFrEF. On average, females were older than males. There was no difference between genders with regard to the type of NVAF or direct oral anticoagulants use. Hypertension was more common in women. History of transient ischemic attack was reported in 3.6% of the patients and cerebrovascular event in 10%, without differences in terms of gender. The percentage of men with elevated embolic risk was higher, but without antithrombotic treatment, in comparison with women.ConclusionsSignificant differences were found according to gender in patients with NVAF and HFrEF, both in CMRF and some comorbidities, as well as in antithrombotic treatment according to embolic and bleeding risk.Copyright: © 2023 Permanyer.

29 keywords...

hide…